PT KALBE FARMA TBK. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,500 IDR | +3.81% |
|
+5.63% | -6.83% |
| 08:00am | Nomura Adjusts Kalbe Farma’s Price Target to 1,900 Rupiahs From 1,850 Rupiahs, Keeps at Buy | MT |
| 04-30 | PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 32,560B 2.05B 161B | Sales 2025 * | 34,951B 2.2B 173B | Capitalization | 66,839B 4.21B 330B |
|---|---|---|---|---|---|
| Net income 2024 * | 3,134B 197M 15.47B | Net income 2025 * | 3,497B 220M 17.26B | EV / Sales 2024 * | 1.94 x |
| Net cash position 2024 * | 3,714B 234M 18.34B | Net cash position 2025 * | 4,587B 289M 22.64B | EV / Sales 2025 * | 1.78 x |
| P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
19.9
x | Employees | 13,062 |
| Yield 2024 * |
2.2% | Yield 2025 * |
2.31% | Free-Float | 40.44% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.81% | ||
| 1 week | +5.63% | ||
| Current month | +3.09% | ||
| 1 month | +3.45% | ||
| 3 months | +1.01% | ||
| 6 months | -7.12% | ||
| Current year | -6.83% |
1 week
1 405.00
1 530.00
1 month
1 375.001 535.00
Current year
1 375.001 620.00
1 year
1 375.002 180.00
3 years
1 240.002 360.00
5 years
830.002 360.00
10 years
830.002 360.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vidjongtius
CEO | Chief Executive Officer | 59 | 31/12/96 |
| Chairman | 62 | 28/02/97 | |
Danny Natalies
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Santoso Oen
BRD | Director/Board Member | 59 | 31/12/99 |
| Chairman | 62 | 28/02/97 | |
Ronny Hadiana
BRD | Director/Board Member | 52 | 31/12/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.30% | 9 M€ | -3.31% | - | |
| 1.91% | 84 M€ | +0.81% | ||
| 1.89% | 2 M€ | -14.14% | ||
| 1.54% | 15 M€ | +18.83% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/05/24 | 1,500 | +3.81% | 53 345 000 |
| 16/05/24 | 1,445 | 0.00% | 36,922,100 |
| 15/05/24 | 1,445 | +2.48% | 36,425,200 |
| 14/05/24 | 1,410 | -1.05% | 36,320,000 |
| 13/05/24 | 1,425 | +0.35% | 37,882,500 |
End-of-day quote INDONESIA S.E., May 16, 2024
More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,500
IDR
Average target price
1,761
IDR
Spread / Average Target
+17.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.83% | 4.2B | |
| +32.07% | 694B | |
| +29.39% | 593B | |
| -1.49% | 371B | |
| +20.12% | 331B | |
| +7.29% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.33% | 169B |
- Stock Market
- Equities
- KLBF Stock
